Previous 10 | Next 10 |
Posters highlight clinically meaningful improvement in HAE symptoms observed in the first hours after treatment with PHVS416 (deucrictibant immediate-release capsules) as compared to placebo ZUG, Switzerland, June 11, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage...
2023-05-08 08:00:47 ET Pharvaris press release ( NASDAQ: PHVS ): Q1 GAAP EPS of -€0.67. Executing from a strong financial position with cash and cash equivalents of €135 million as of March 31, 2023 For further details see: Pharvaris GAAP EPS of -...
Top-line data from CHAPTER-1, a proof-of-concept Phase 2 study of PHVS416 (immediate-release deucrictibant capsules) for the prophylactic treatment of HAE, anticipated by YE2023 Executing from a strong financial position with cash and cash equivalents of €135 million as of March 31, ...
ZUG, Switzerland, May 06, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced two oral presentations and three poster presentations highl...
Top-line data from CHAPTER-1, a proof-of-concept Phase 2 study of PHVS416 for the prophylactic treatment of HAE, anticipated in 2H2023 26-week non-clinical toxicology study intended to address the clinical holds in the U.S. initiated; submission of study results anticipated by YE2023 Ad...
ZUG, Switzerland, March 18, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced an oral presentation of positive data from its Phase 2 RA...
ZUG, Switzerland, March 02, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that management will participate in two upcoming investor...
ZUG, Switzerland, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced a poster detailing positive data from its Phase 2 RAPIDe-1...
Summary BioCryst's main value driver, ORLADEYO, is already profitable in its second year on the market and generated over $250 million in revenue in 2022. ORLADEYO is successfully differentiating itself in a multi-billion dollar market and is on track to achieve blockbuster status in a ...
ZUG, Switzerland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that management will present at the SVB Securities Global ...
News, Short Squeeze, Breakout and More Instantly...
Pharvaris N.V. Company Name:
PHVS Stock Symbol:
NASDAQ Market:
2024-06-13 23:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hours High treatment satisfaction of deucrictibant driven by favorable effectiveness subdomain score compared to placebo ZUG, Switzerland, June 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasd...
2024-06-02 07:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...